This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Life Technologies Launches Compendia Oncomine® NGS Power Tools For Cancer Researchers, Discovers Novel Gene Fusions

CARLSBAD, Calif., June 10, 2013 /PRNewswire/ --  Life Technologies Corporation (NASDAQ: LIFE) announced today the introduction of Oncomine® Next Gen Sequencing Power Tools, an analytics offering that will allow cancer researchers to explore results from in-depth analysis of next generation sequencing (NGS) data, including data from The Cancer Genome Atlas. In total, more than 4,500 paired tumor and samples have been analyzed to date.

"NGS has significant potential to deliver insights into what drives cancers and how the disease might be combated," said Dan Rhodes, Ph.D., head of medical science informatics for Life Technologies.  "However, the field has only begun to take advantage of the enormous amounts of data becoming available. The Oncomine NGS Power Tools provide simple access to comprehensive findings, many of them novel, from a team with a proven track record of mining scientific value from big data."

Oncomine® NGS Power Tools constitutes a suite of software tools that enable cancer researchers to easily survey novel predicted driver mutations and gene fusions across all cancers and within two dozen specific cancers types, as well as explore simple summary analyses that integrate multiple types of gene and pathway aberrations with clinical data.

In addition to basic research applications, the NGS tools also provide a foundation for specialized biomarker services to pharma and biotech customers in their efforts to evaluate NGS data for biomarker and companion diagnostic development.   

With collaborators from the University of Michigan Medical School, Life Technologies scientists used the NGS Power Tools to discover FGFR gene fusions across a range of cancer types. These results are reported in the current issue of Cancer Discovery.

The investigators discovered FGFR fusions across a highly diverse set of nine distinct tumor types, including lung squamous cell cancer, bladder cancer, thyroid cancer, oral cancer, glioblastoma, and head and neck squamous cell cancer. Normal cell lines transfected with fusion constructs exhibited enhanced growth that was sensitive to FGFR inhibitors, indicating that the fusion genes were in fact acting to drive the cancers.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 0.00%
FB $118.06 0.00%
GOOG $695.70 0.00%
TSLA $222.56 0.00%
YHOO $36.00 0.00%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs